Clinical Validation of Freenome Multiomics Blood Test for Lung Cancer Screening

Conditions

• Lung Cancer Diagnosis

Eligibility Criteria

Sex

ALL

Age

50 Years - N/A

Healthy Volunteers

Not accepted

Interventions

• blood draw — DIAGNOSTIC_TEST
  Subjects who provide informed consent and meet the eligibility criteria will have 50 ml of blood collected and sent to Freenome or Freenome's designee for processing, testing, and storage, and will then complete a standard-of-care screening LDCT.

Study Details

The PROACT LUNG study is a prospective multi-center observational study to validate a blood-based test for the early detection of lung cancer by collecting blood samples from high-risk participants who will undergo a routine, standard-of-care screening Low-Dose Computed Tomography (LDCT).

Key Dates

Start date

Nov 28, 2023

Status verified

Aug 2025

Primary completion

Jun 15, 2026

Completion

Jun 15, 2027

Study Design

Enrollment

20,000 participants (estimated)

Primary Outcome Measure

Sensitivity and specificity in detecting lung cancer [ Time Frame: 12-Months ]

Central Contacts

• Harris Naemi, BS
  925-322-6486
  [email protected]

Locations (36)

Find similar trials in Los Angeles, CA

Related Studies

• Evaluating the Implementation of a Comprehensive Multilevel Virtual Oncology Program Among Veterans Diagnosed With Lung, Colorectal, Prostate, and Breast Cancers in the US Department of Veterans Affairs
  Recruiting · NYU Langone Health · Brooklyn, New York
• Increasing Lung Cancer Screening Uptake Among Emergency Department Patients
  Recruiting · University of Rochester · Rochester, New York